EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EMERGING DRUGS OF ABUSE IN THE CHRONIC PAIN POPULATION: A CLINICAL PHARMACOLOGY PERSPECTIVE ON KRATOM, NOVEL SYNTHETIC OPIOIDS, DESIGNER BENZODIAZEPINES, GABAPENTINOIDS, XYLAZINE, AND KETAMINE

Fondazione Paolo Procacci

Advancements in Health Research · 06.05.2026 · 3 (s1)

DOI: 10.4081/ahr.2026.152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advancements in Health Research, online erschienen am 06.05.2026. Verfasst von Fondazione Paolo Procacci. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims. Chronic pain patients increasingly self-medicate with unregulated and emerging psychoactive substances, driven by opioid prescribing restrictions, cost barriers, and the widespread perception that "natural" alternatives are safe. Pain specialists face a critical knowledge gap: none of the substances reviewed in this analysis are detectable on standard immunoassay urine drug screens, rendering conventional monitoring strategies fundamentally insufficient for this evolving patient population. The aim is to characterize the pharmacology, clinical risk profiles, drug interaction mechanisms, regulatory status, and toxicological detection requirements of six emerging drug classes of direct relevance to pain medicine practice: kratom (Mitragyna speciosa), novel synthetic opioids (nitazenes), designer benzodiazepines, gabapentinoids (in the context of misuse), xylazine, and ketamine.

Methods

Narrative review of published peer-reviewed literature, pharmacovigilance databases, and regulatory agency communications (FDA, DEA, EMCDDA, EMA), supplemented by large-scale survey data. Analysis was conducted from a clinical pharmacology perspective with primary emphasis on patient safety implications for pain medicine practitioners operating in international settings.

Results

Kratom, used by an estimated 1.7 billion individuals globally, produces biphasic dose-dependent effects via mu-opioid receptor agonism and CYP3A4/CYP2D6 inhibition, creating clinically silent pharmacokinetic interactions with co-prescribed analgesics. Nitazenes — benzimidazole-class full MOR agonists 10–100× more potent than morphine — are increasingly detected in illicit opioid supplies across North America and Europe and require LC-MS/MS for identification, which is unavailable on standard panels. Designer benzodiazepines (etizolam, clonazolam, and flualprazolam) escape standard immunoassay detection entirely and produce respiratory depression synergistic with prescribed opioids. Gabapentinoid misuse is implicated in over 35% of opioid-related deaths in the United Kingdom. Xylazine adulteration of fentanyl creates a dangerous partial naloxone-response scenario with pathognomonic necrotic wound presentation. Ketamine’s expanding therapeutic use coexists with irreversible uropathy documented in 20–30% of chronic recreational users. Across all six substance classes, standard urine drug screens are uniformly inadequate; targeted confirmatory testing (LC-MS/MS, GC-MS) and specific, non-judgmental patient questioning are required.

Conclusions

Emerging drugs of abuse represent a clinically urgent and underrecognized patient safety challenge in pain medicine. Pain specialists must adopt substance-specific screening strategies, update patient communication frameworks, and engage professional societies to address the regulatory and educational gaps the rapidly evolving landscape exposes. Collaborative international pharmacovigilance and sustained research investment are essential to protect patients across jurisdictions.

Zitieren

APA

Procacci, F. P. (2026). EMERGING DRUGS OF ABUSE IN THE CHRONIC PAIN POPULATION: A CLINICAL PHARMACOLOGY PERSPECTIVE ON KRATOM, NOVEL SYNTHETIC OPIOIDS, DESIGNER BENZODIAZEPINES, GABAPENTINOIDS, XYLAZINE, AND KETAMINE. Advancements in Health Research, 3(s1). https://doi.org/10.4081/ahr.2026.152

Vancouver

Procacci FP. EMERGING DRUGS OF ABUSE IN THE CHRONIC PAIN POPULATION: A CLINICAL PHARMACOLOGY PERSPECTIVE ON KRATOM, NOVEL SYNTHETIC OPIOIDS, DESIGNER BENZODIAZEPINES, GABAPENTINOIDS, XYLAZINE, AND KETAMINE. Advancements in Health Research. 2026;3(s1). doi:10.4081/ahr.2026.152

BibTeX
@article{Procacci2026,
  author = {Procacci, Fondazione Paolo},
  title = {EMERGING DRUGS OF ABUSE IN THE CHRONIC PAIN POPULATION: A CLINICAL PHARMACOLOGY PERSPECTIVE ON KRATOM, NOVEL SYNTHETIC OPIOIDS, DESIGNER BENZODIAZEPINES, GABAPENTINOIDS, XYLAZINE, AND KETAMINE},
  journal = {Advancements in Health Research},
  year = {2026},
  volume = {3},
  number = {s1},
  doi = {10.4081/ahr.2026.152}
}
Kostenlos starten →